Advances in Antiviral Drug Design Ebook
You're about to purchase a Downloadable Ebook
Hi, sorry for the interruption!
We're repeating some important information here to ensure that you're making an informed purchase. Please review it.
- Don't get caught unaware. Preview ebook and open the sample ebook on each of your intended devices before continuing.
- You will need a Free 3rd-party application that can read the intermediate .acsm file you will receive as download. PDF/Epub format is downloaded automatically by the application thereafter. Please install the necessary software first on your intended device of use.
- e-Book can be copied on up to 6 devices that must have the same Adobe ID
- We can only keep the download on our site until the ebook publishers/distributors authorize us to do so. Please keep a backup.
- Printing is permitted.
- You can copy text from file.
Refunds are not allowed after the ebook is opened so please open the ebook directly on your intended device. Refund requests should be recieved within 7 days after download is made available. Of course, if you get an incorrect ebook ( different from what is mentioned in the title) or if the ebook doesn't open on the initial device, then we'll assist with fixing the issue or get you a refund if a timely fix isn't available.
We currently only provide ticket (online form submission) or email support. Rest assured that you're in good hands; customers like our professional service!
Publication Date: December 2003
File Size: 3612 Kbytes
Restrictions set by Publisher:
- Text-to-speech feature not available.
- Printing is permitted.
- You can copy text from file.
- Free application Adobe Digital Editions, Aldiko reader, or Bluefire reader required .
- Check Supported devices and software requirements .
- Ebooks once opened are non-refundable. View return policy .
- OnlineBookPlace.com Store Reviews on Google and Yahoo
The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.
First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.
Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.
Third, as all currently available PIs can be described as “peptidomimetic”, and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.
Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.
Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone “upstream” in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.
Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.
The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses.
Should you buy this Ebook?
We've put together a collection of resources to help you make a decision regarding whether you should buy this Ebook from us.
- Is your device one of these? Ebook reading software will work on the following devices: Windows, Mac, Android 2.2+ Devices, IPad (iOS 3+), IPhone (iOS 3+), Kindle Fire. Several other devices are also supported by the software.
- Compare prices. Our price is $142.00. If you would like to research our competitors to see their prices. Here're some places to look:
Why should you buy Ebooks from onlinebookplace.com?
We've had 1000s of downloads so far and with over 300000+ Ebooks to choose from, onlinebookplace.com is becoming a favorite Ebook Store for many. Allow us to win you over with our competitive pricing, upfront policies and diligent customer service.
- Every Ebook page on onlinebookplace.com has information on restrictions that publishers have placed on the Ebook along with a clear indication of software required to read the Ebooks.
- If ratings for an Ebook are available from one of several sources online, then we've attempted to get those to help you make a better purchasing decision about the Ebook. Reviews from Goodreads (a popular reviews site) are provided on the same if they're available.
- In most cases, we've also attempted to get you links to the Ebook on our competitor's site so that you can compare prices with relative ease.
- We use McAfee to scan for any vulnerabilities in the system to ensure that any information that you give us does not fall into the wrong hands.
- We use Paypal, a trusted 3rd party payment provider to accept Payments -- your payment information doen't reside with us. Any information that does end up with us is safe.
After installing the appropriate app for your device, try a Sample Download (Sherlock Holmes from Project Gutenberg) before purchase. The sample is only for checking device compatibility.
Check below for device compatibility and any free 3rd-party software requirements. Choice of what ebook reading app to use is yours, we only present a few common apps that several customers of ours have preferred. You should be able to transfer your purchase to more than one (upto 6) compatible devices as long as your ebook-reading apps have been registered with the same Adobe ID before opening the file.
Windows/Mac PC or Laptop
Free app Adobe Digital Editions required. Note that this software is not the same as Adobe Reader.